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ABSTRACT 
In patients with chronic kidney disease (CKD), inflammation and malnutrition are harmful 
and highly prevalent conditions with influence on the atherosclerotic process and outcome. 
The risk of cardiovascular disease (CVD) is substantially increased in CKD patients 
compared with healthy individuals. In uremic patients, homocysteine (Hcy) is a marker of 
disturbed metabolism and is suggested as a potential cardiovascular risk factor. Several 
inflammatory markers are associated with cardiovascular morbidity and mortality. Together 
with CRP and serum amyloid P (SAP), pentraxin 3 (PTX3) is a protein belonging to the 
through evolution highly conserved pentraxin family and is involved in the regulation of the 
innate immune system. In contrast to CRP, which is synthesized in the liver, PTX3 is 
produced in the vasculature, and circulating levels mirror local inflammatory processes. The 
aim of this thesis was to study inflammatory and metabolic biomarkers associated with 
cardiovascular risk in i) elderly individuals in the general population, ii) patients with CKD 
and iii) dialysis patients. We also investigated homocysteine and PTX3 as predictors of 
mortality in dialysis patients. In paper I we measured the reduced, free and total forms of 
Hcy in plasma of patients with peritoneal and hemodialysis (HD) treatment and in patients 
with CKD stage 3 to 5. The more harmful form of Hcy, the reduced Hcy form (rHcy), was 
higher in all patients with impaired renal function than in healthy controls. In dialysis 
patients, the ratio of reduced and total Hcy (rHcy/tHcy) was higher than in CKD patients and 
the ratio further increased during HD treatment. In paper II we investigated PTX3 and 
estimated glomerular filtration rate (eGFR) in two large community cohorts of elderly women 
and men in Uppsala. In a cross-sectional analysis, higher PTX3 levels were associated with 
lower GFR estimated from plasma cystatin C levels. In a longitudinal analysis, PTX3 
independently predicted incidence of CKD as estimated by a drop of eGFR below 60 
mL/min*1.73 m
2
 BSA. These findings suggest that inflammatory processes are activated and 
play a role in the early stages of CKD. In paper III plasma levels of PTX3, CRP, albumin 
and Hcy were measured twice over a three-month period in HD patients. PTX3 had the 
highest intra-individual variation followed by albumin, CRP and Hcy. Furthermore, 
persistently elevated PTX3, increasing levels of CRP, decreasing levels of albumin and 
persistently low Hcy levels over three months were associated with a high mortality risk after 
adjustment for other risk factors. In paper IV the release of PTX3 in response to 
inflammatory signals induced during a HD treatment was investigated. The plasma 
concentration of PTX3 was measured at the start and after 30, 60, 120, 180 and 240 minutes 
of the HD session. The increase of PTX3 was significant after 60 minutes, while CRP levels 
did not change during hemodialysis. We found that PTX3 is a sensitive marker of HD-
induced inflammatory activity, probably because it is rapidly released from neutrophil 
granules on immune activation during HD. In conclusion, accumulation of reduced Hcy in 
CKD and dialysis patients has potentially toxic effects on the vasculature. However, Hcy is 
not a reliable risk marker in patients with chronic kidney disease. PTX3 has a high intra-
individual variation over three months, but the levels in CKD patients are associated with 
CVD and mortality. In elderly individuals in the community, PTX3 was associated with CKD 
incidence over a 5-year follow-up period. PTX3 is a quick and sensitive biomarker that has 
the potential to be an important clinical tool in patients with early and late stages of CKD, as 
well as in dialysis patients.  
 2 
LIST OF SCIENTIFIC PAPERS 
I. Sjöberg B, Anderstam B, Suliman M and Alvestrand A. “Plasma reduced 
homocysteine and other aminothiol concentrations in patients with CKD”, 
American Journal of Kidney Disease, 2006, Vol 47; No 1, 60-71. 
II. Sjöberg B, Qureshi AR, Heimbürger, Stenvinkel P, Lind L, Larsson A, 
Bárány P and Ärnlöv J. “Association between the inflammatory marker 
pentraxin 3, glomerular filtration rate and CKD incidence in two 
community-based cohorts”, manuscript. 
III. Sjöberg B, Snaedal S, Stenvinkel P, Qureshi AR, Heimbürger O and Bárány 
P. “Three-month variation of plasma pentraxin 3 compared with C-reactive 
protein, albumin and homocysteine levels in haemodialysis patients”, 
Clinical Kidney Journal 2014; 7: 373-379. 
IV. Sjöberg B, Qureshi AR, Anderstam B and Alvestrand A and Bárány P. 
“Pentraxin 3, a sensitive early marker of hemodialysis-induced 
inflammation”, Blood Purification 2012; 34: 290-297. 
  3 
CONTENTS 
1 Introduction ..................................................................................................................... 7 
1.1 Kidney, normal structure and function ................................................................. 7 
1.2 Kidney, pathology, chronic kidney disease (CKD) stage 1 – 5 ........................... 8 
1.2.1 Causes of CKD .......................................................................................... 8 
1.2.2 CKD stages ................................................................................................ 8 
1.2.3 Prevalence, incidence and gender differences .......................................... 9 
1.2.4 Uremic syndrome, metabolic disturbances and corrective 
treatment .................................................................................................... 9 
1.2.5 Renal replacement therapy ...................................................................... 11 
1.3 Risk factors for mortality .................................................................................... 11 
1.3.1 Cardiovascular disease and chronic kidney disease ............................... 11 
1.3.2 Malnutrition ............................................................................................. 12 
1.4 Inflammation ....................................................................................................... 12 
1.4.1 Inflammation and CVD ........................................................................... 12 
1.4.2 The role of inflammation in CKD patients ............................................. 12 
1.4.3 Inflammatory markers in CKD ............................................................... 13 
1.5 Homocysteine ...................................................................................................... 15 
1.5.1 Mechanisms of Hcy ................................................................................ 15 
1.5.2 Hyperhomocysteinaemia......................................................................... 15 
1.6 Interventions ........................................................................................................ 16 
1.6.1 Vitamins .................................................................................................. 16 
1.6.2 Dialysis .................................................................................................... 16 
1.6.3 Anti-inflammatory and anti-oxidative interventions .............................. 18 
2 The aims of the studies .................................................................................................. 19 
2.1 Overall aims ......................................................................................................... 19 
2.2 Specific aims ........................................................................................................ 19 
3 Methods ......................................................................................................................... 21 
3.1 Study populations ................................................................................................ 21 
3.1.1 Study one ................................................................................................. 21 
3.1.2 Study two ................................................................................................. 21 
3.1.3 Study three ............................................................................................... 23 
3.1.4 Study four ................................................................................................ 23 
3.2 Study procedure ................................................................................................... 23 
3.2.1 Study one ................................................................................................. 23 
3.2.2 Study two ................................................................................................. 23 
3.2.3 Study three ............................................................................................... 23 
3.2.4 Study four ................................................................................................ 24 
3.3 Biochemical analysis ........................................................................................... 25 
3.3.1 Homocysteine .......................................................................................... 25 
3.3.2 Pentraxin 3 ............................................................................................... 26 
3.3.3 Cystatin C ................................................................................................ 26 
 4 
3.3.4 CRP and other inflammatory markers .................................................... 26 
3.3.5 Others ...................................................................................................... 27 
3.4 Statistical analysis ............................................................................................... 27 
3.4.1 Paper I ...................................................................................................... 27 
3.4.2 Paper II .................................................................................................... 27 
3.4.3 Paper III ................................................................................................... 28 
3.4.4 Paper IV ................................................................................................... 29 
3.5 Ethical approvals ................................................................................................. 29 
4 RESULTS AND DISCUSSION ................................................................................... 31 
4.1 Plasma reduced homocysteine in patients with CKD (study I) ......................... 31 
4.2 Association between the inflammatory marker PTX3, glomerular 
filtration rate and CKD incidence in two community-based cohorts (study 
II) .......................................................................................................................... 34 
4.3 Three-month variation of plasma PTX3 compared with CRP, albumin and 
homocysteine (study III) ..................................................................................... 36 
4.3.1 Variability ................................................................................................ 36 
4.3.2 Mortality risk ........................................................................................... 37 
4.3.3 Summary ................................................................................................. 39 
4.4 PTX3, a sensitive early marker of hemodialysis-induced inflammation 
(study IV) ............................................................................................................. 40 
4.4.1 PTX3 during a HD session in 22 patients .............................................. 40 
4.4.2 PTX-3 during repeated HD sessions ...................................................... 40 
4.4.3 Impact of low-flux membranes, high-flux membranes and 
hemodiafiltration (HDF) on inflammatory markers............................... 41 
5 Summary and conclusions ............................................................................................ 43 
5.1 Homocysteine ...................................................................................................... 43 
5.2 Pentraxin 3 ........................................................................................................... 43 
5.3 Strengths and limitations ..................................................................................... 44 
5.4 Future perspectives .............................................................................................. 44 
6 Svensk sammanfattning ................................................................................................ 47 
7 Acknowledgements ....................................................................................................... 49 
8 References ..................................................................................................................... 51 
 
  
  5 
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1 INTRODUCTION 
 
Patients with chronic kidney disease (CKD) have a substantial increase in cardiovascular 
morbidity and mortality compared with the general population (1, 2). The cardiovascular risk 
is increased already in the early stages of CKD and increases several-fold during disease 
progression. Patients with hemodialysis or peritoneal dialysis have the highest mortality risk, 
especially in the first three months after dialysis initiation. Patients with a kidney transplant 
have a much higher survival rate than dialysis patients (3, 4). During the last decades, there 
has been some interest in non-cardiovascular risk factors, such as inflammation, and their 
association to the atherogenic process. Inflammatory markers can predict CVD and all-cause 
mortality in the general population as well as in dialysis patients (5, 6). The most frequently 
used inflammatory marker is C-reactive protein (CRP), but other markers such as pentraxin 3 
(PTX3) may add information about the complex association between inflammation and 
cardiovascular disease (CVD) (7-9). Markers of metabolic disturbances in uremia, such as 
homocysteine (Hcy), have also been suggested as potential modifiable cardiovascular risk 
factors (10, 11). 
 
1.1 KIDNEY, NORMAL STRUCTURE AND FUNCTION 
 
In a young healthy person, each kidney is built up of one million nephrons, the functional 
units of the kidney, see schematic figures 1 and 2. 
 
 
Figure 1. The structure of the kidney. 
  
 
The kidneys have several important functions beyond the removal of toxic waste products 
(uremic toxins) and regulation of the fluid balance of the body. Blood pressure is regulated by 
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the renal vessels (oncotic and hydrostatic pressure gradient and auto regulation) and the 
synthesis of red blood cells is regulated by the hormone erythropoietin, produced in the 
juxtaglomerular cells in the kidney, which stimulates the synthesis of red blood cells in the 
bone marrow. Further, the kidneys handle the regulation of the acid-base balance and the 
conversion of inactive to active D-vitamin.  
 
Figure 2. The structure of the nephron. 
 
The glomeruli are built up of vessels and the renal blood flow is 1.2 L/min, 25 % of the 
normal cardiac output of 5 L/min in a young healthy adult. The renal plasma flow is 0.65 
L/min, 20 % is filtered and the normal glomerular filtration rate (GFR) is 125 mL/min. 
 
1.2 KIDNEY, PATHOLOGY, CHRONIC KIDNEY DISEASE (CKD) STAGE 1 – 5  
1.2.1 Causes of CKD  
Diabetes nephropathy is considered to be the most common cause of chronic kidney disease 
world-wide, followed by hypertension/renovascular disease (12). In Sweden, 
hypertension/renovascular disease is the most common cause of CKD, followed by diabetes 
nephropathy, but among prevalent patients with renal replacement therapy (RRT), chronic 
glomerulonephritis (25 %) is the most common cause of CKD, followed by diabetes 
nephropathy (18 %), even though diabetes nephropathy is the most common diagnosis for 
patients initiating dialysis treatment. The third most common diagnosis among patients with 
RRT is adult polycystic kidney disease (10 %) followed by hypertension (8 %), 
pyelonephritis (4 %), unknown cause (1 %) and others (33 %) (13). 
 
1.2.2 CKD stages 
Chronic kidney disease (CKD) is defined as a state of kidney damage and/or decreased 
glomerular filtration that lasts for at least 3 months (14). Patients with CKD often have a 
declining kidney function over many years. Current classification of CKD is based on cause 
(glomerular diseases, tubule-interstitial diseases, vascular diseases, cystic and congenital 
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diseases), GFR category and albuminuria category. 
  
 
Table 1. GFR categories in CKD in current classification system. 
GFR category  GFR (mL/min/1.73 m²) Terms 
G1 > 90 Normal or high 
G2 60 – 89 Mildly decreased 
G3a 45 – 59 Mildly to moderately decreased* 
G3b 30 – 44 Moderately to severely decreased 
G4 15 – 29 Severely decreased 
G5 < 15 Kidney failure 
*Relative to young adult level. In the absence of evidence of kidney damage such as albuminuria, neither 
GFR category G1 nor G2 fulfill the criteria for CKD. 
 
1.2.3 Prevalence, incidence and gender differences 
 
In the general adult population, CKD is a global health burden and the world-wide 
prevalence of CKD is 10 – 15 % in both low-income and high-income countries (15, 16). 
The prevalence of RRT in Sweden was 938 individuals per million inhabitants in 2013. The 
majority of the 9,051 patients with RRT were renal transplanted (rtx, 57 %) and 3,857 
patients had dialysis, hemodialysis (HD, 33 %) or peritoneal dialysis (PD, 9 %). The 
number of patients with RRT more than doubled in 20 years and the number of HD patients 
increased from 1,124 in 1990 to 2,881 in 2013 (13), even though the increase rate has 
diminished over the last decade. There is a consistent gender difference in patients with 
CKD in the late stages; in most populations, 35 – 40 % are women and 60 – 65 % are men. 
 
1.2.4 Uremic syndrome, metabolic disturbances and corrective treatment 
 
At the early stages of CKD, stage 1 – 3, there are often few symptoms and renal failure is 
often discovered during investigation of hypertension or CVD. In CKD stage 4 – 5 several 
symptoms appear.  
A Anemia develops because of reduced renal synthesis of erythropoietin starts in CKD 
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stage 3 and develops slowly and the patient may not notice symptoms until Hb is 
below 90 g/L. Most CKD patients respond to anemia treatment in the form of 
erythropoietin and iron with increasing Hb levels to a target interval between 100 – 120 
g/L (17, 18). 
B Increased catabolism and decreased synthesis of proteins may contribute to 
muscular weakness and metabolic acidosis. Loss of appetite and prescribed low 
protein diet may induce insufficiency of essential amino acids, which aggravates the 
risk of malnutrition and weight loss (19). Medication with sodium bicarbonate can 
regulate the acidosis, supplementation with essential amino acids and help from a 
dietitian can reduce uremic symptoms. 
C When GFR diminishes, phosphate accumulates and the plasma calcium level is low, 
because of reduced renal synthesis of the active vitamin D metabolite calcitriol 
1.25(OH)₂-vitD₃ (calcitriol). Disturbed action of the phosphaturic hormone fibroblast 
growth factor 23 (FGF23) and its co-factor klotho, as well as increased production of 
parathyroid hormone (PTH), all contribute to development of mineral bone disorder in 
CKD (MBD-CKD) (20, 21). MBD-CKD leads to skeletal changes, for example osteitis 
fibrosa, but also increased risk for calcifications in vessels and in the heart (coronary 
arteries), contributing to an increased risk for CVD (22). Calcifications in the muscles 
and joints may cause tenderness in muscles and arthralgia. Diet restrictions and 
dialysis regimens are important tools to correct calcium-phosphate imbalances. 
Furthermore, many patients need phosphate binders, vitamin D supplementation 
and/or calcimimetic medication to bridge the negative effects of an impaired calcium-
phosphate balance (23). 
D Hypertension, associated to salt and water retention in CKD patients, is an early 
consequence of impaired kidney function and adequate antihypertensive treatment is 
recommended. Overt fluid overload and disturbed electrolyte balance often appear late 
in CKD stage 5, with risk of life-threatening pulmonary edema and hyperkalemia. 
E There are many symptoms of uremia and these change as GFR lowers and vary 
between individuals. Symptoms include fatigue, altered taste sensation, nausea, 
vomiting, weight loss, weakness, mental tiredness, decreased ability to concentrate, 
gastro-intestinal symptoms, sleeping problems, edema, bleeding tendency, restless legs 
and itchiness. Severe complications are lung edema with respiratory distress, uremic 
pericarditis with or without chest pain, seizures and unconsciousness. 
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1.2.5 Renal replacement therapy 
 
When a patient with declining kidney function reaches GFR 5 – 10 mL/min/1.73 m², it is 
time to start RRT (24). The preferable choice is a kidney transplant, but limited availability 
of organs and high risks for elderly or patients with severe CVD are the reasons why most 
patients reaching CKD 5 start with dialysis. There are two different modalities of dialysis; 
the most common is hemodialysis, where blood passes through a dialyzer with a semi-
permeable membrane and the uremic toxins and fluid volume are removed. Standard 
hemodialysis treatment is performed for four hours, three times a week. The other modality 
is peritoneal dialysis where exchange of dialysis fluid in the abdomen four times a day 
removes uremic toxins and fluid from plasma through the peritoneal membrane. After a 
successful replacement of a transplanted kidney, the recipient often reaches a GFR of 40 – 
60 mL/min/1.73 m², while both dialysis types have less effective clearance, resulting in 
increased inflammation, malnutrition and a higher mortality risk (25, 26).  
 
1.3 RISK FACTORS FOR MORTALITY  
 
1.3.1 Cardiovascular disease and chronic kidney disease 
 
Patients with chronic kidney disease have generally increased arteriosclerosis, left 
ventricular hypertrophy, congestive heart disease and coronary heart disease. Individuals 
with mild CKD (stage 1 – 2) have an increased cardiovascular risk (27, 28) and the 
incidence of cardiovascular death in dialysis patients is up to 20 times higher than in age- 
and sex-matched controls in the general population. For dialysis patients below 45 years of 
age, the cardiac mortality risk increases over 100-fold (29).The traditional risk factors for 
CVD and mortality in the general population, such as diabetes mellitus, hypertension, 
hypercholesterolaemia, smoking and physical inactivity, are highly prevalent in patients 
with mild CKD (stage 1 – 3). Patients with CKD also have a number of non-traditional risk 
factors such as fluid overload, anemia, inflammation, oxidative stress, and disturbances in 
calcium and phosphate levels, as well as hyperparathyroidism which may accelerate the 
arteriosclerosis process (30). CKD patients develop both atherosclerosis with calcium 
plaques in the intima layer and arteriosclerosis with hyperplasia of smooth muscle cells and 
subsequently often extensive calcifications in the media layer of the arteries. The vascular 
calcifications are widespread and affect the coronary arteries, aorta and heart valves (31). 
 
However, compared with what is observed in the general population, several cardiovascular 
risk factors associated with nutritional status are reversed in dialysis patients, e.g. obese 
dialysis patients have lower mortality risk than non-obese (32) and low plasma cholesterol 
and low serum creatinine before hemodialysis are factors associated with increased 
mortality risk (19). 
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Patients with chronic heart failure without underlying kidney disease often have decreased 
GFR. This is, in part, a consequence of reduced cardiac output followed by reduced renal 
blood flow. There is a physiological compensatory increase of the renal vascular resistance 
and retention of fluid and sodium to maintain the intra-glomerular pressure. This often 
worsens the heart failure and when blood pressure cannot be sustained, the kidney function 
is affected. Treatment of patients with chronic heart failure followed by reduced GFR 
requires a balance of ACEI/ARB, beta blockers, furosemide and, in early stages, 
aldosterone antagonists. Patients also need frequent check-ups measuring creatinine, eGFR, 
electrolytes, blood pressure and edema level. The kidney function is dependent on the 
progress of the heart failure. 
1.3.2 Malnutrition 
 
Patients with CKD stage 4 – 5 and dialysis patients often suffer from protein-energy 
wasting which is linked to both inflammation and worse cardiovascular outcome. Protein-
energy wasting also occurs among obese hemodialysis patients, together with significant 
skeletal muscle loss (obese sarcopenia) (33). Serum albumin is a poor marker of the 
nutritional state in dialysis patients since albumin is an acute-phase reactant and is 
associated with inflammation, rather than being a marker of protein-energy wasting (34). 
Fluid status also has some influence on albumin levels. 
 
Obesity is associated with persistent low-grade inflammation in the general population and 
results in increased risk for inflammatory diseases including atherosclerosis and diabetes 
mellitus. Obese individuals have elevated plasma levels of CRP, IL6, IL10 and TNFα (35). 
In contrast, serum levels of PTX3 are inversely associated with BMI and waist 
circumference (36, 37). In community-based cohorts and longitudinal data over five years 
showed that weight loss was associated with an increase of PTX3 levels (37).  
 
1.4 INFLAMMATION  
 
1.4.1 Inflammation and CVD 
 
Today, atherosclerosis is seen as an inflammatory disease involving the innate immune 
system. In CKD patients, persistent inflammation strongly contributes to the accelerated 
arterial disease, which results in an increased risk of cardiovascular morbidity and 
mortality, where dialysis patients suffer the highest risk (38, 39). 
1.4.2 The role of inflammation in CKD patients 
 
Independent of dialysis modality, exposure to dialysis membranes and/or contaminated 
dialysis fluid, dialysis patients have increased plasma levels of CRP, interleukin 1 (IL1), 
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interleukin 6 (IL6) and tumor necrosis factor alpha (TNFα) without clinical symptoms of 
on-going inflammation or infection. The long and persistent effect of inflammation in 
dialysis patients seems to be detrimental and the risk for mortality and incident 
cardiovascular complications is associated to plasma levels of inflammatory markers (40-
46). 
1.4.3 Inflammatory markers in CKD  
1.4.3.1 CRP  
The acute-phase protein CRP is the prototype marker for inflammation used in clinical 
settings and high CRP predicts cardiovascular mortality in the general population (47, 48), 
in CKD and in dialysis patients (49, 50). CRP is implicated in endothelial dysfunction and 
CRP synthesis in the liver is stimulated by IL6 in response to tissue damage or bacteria and 
can be detected systemically 6 – 8 hours after injury. In the clinic, increased circulating 
CRP levels are easy to detect, because CRP has a long half-life of 19 hours. CRP does not 
change during one HD treatment and for that reason CRP is not an ideal marker to assess 
inflammatory reactions during HD (51-53). 
1.4.3.2 Albumin 
Low-grade inflammation is an important cause of protein-energy wasting in CKD patients, 
a process that eventually leads to malnutrition and low serum albumin (54). However, 
albumin is mainly considered an inflammatory marker rather than a marker for nutritional 
status and because of this, hypoalbuminaemia is associated with poor outcome in dialysis 
patients (35, 55). 
1.4.3.3 PTX3 
The long pentraxin PTX3 is part of the innate immune system together with the short 
pentraxins CRP and serum amyloid P, see figure 3 below (56). Pentraxins are members of a 
family of ancient proteins with well-preserved structure throughout evolution (57-59). 
Pentraxin 3 is produced in the vasculature by different cell types, including endothelial 
cells, smooth muscle cells, fibroblasts, mononuclear phagocytes and epithelial cells, in 
response to IL1β and TNFα as well as lipopolysaccharides from bacteria (60). Neutrophil 
granules act as a reservoir of PTX3 and will rapidly release PTX3 in response to 
inflammatory signals or microbial recognition (61). PTX3 can, therefore, in thirty minutes 
systemically reflect the acute and local inflammation in the vasculature (62). PTX3 acts like 
a tuner for the immune system and is involved in pathogen recognition, complement 
activation and regulation, which improves the defense against various infections (63, 64). 
PTX3 is involved in the development of atherosclerotic plaque and in angiogenesis in some 
way, but its role is debated. It is unclear whether PTX3 is part of the atherogenic process, is 
a tuner of the immune system’s protective qualities or a biomarker of processes in the 
vasculature (65). Studies show that PTX3 has an active part in foam formation in plaques 
and takes part in activation of the classical complement cascade (66-68), but on the other 
hand, a study from 2011 shows cardio-protective effects of PTX3 in healthy men (69). 
PTX3 also seem to be protective in acute myocardial infarction (70, 71).  
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Figure 3. Role of PTX-3 in the innate immune system. Toll-like receptors are activated by inflammation. 
While CRP secretion from the liver is stimulated by systemic IL-6, PTX-3 is released locally in the 
vasculature. IL-10 amplifies PTX-3 secretion. PTX-3 and CRP are involved in pathogen recognition, 
complement activation and regulation. Published with permission (56).  
 
1.4.3.4 TNFα 
The pro-inflammatory cytokine TNFα is part of the regulation of pro- and anti-
inflammatory mediators and provides rapid defense against infection, but is fatal in excess. 
In addition to being involved in plaque instability, TNFα is implicated in myocardial 
infarction and acute ischemic disorders (72). TNFα levels and activity are upregulated in 
patients with CKD stage 5 (45).  
1.4.3.5 IL6 
The pro-inflammatory cytokine IL6 has a direct inflammatory effect in the myocardial and 
peripheral vasculatures, due to the IL6-regulated activation of leucocytes and endothelial 
cells in the atherosclerotic process. An increased plasma level of IL6 predicts 
cardiovascular and total mortality in CKD stage 5 patients better than the most frequently 
used inflammatory marker CRP (73). The synthesis of CRP in the liver is induced by an 
increase of plasma IL6, see figure 3. 
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1.5 HOMOCYSTEINE  
1.5.1 Mechanisms of Hcy 
 
Homocysteine (Hcy) is a sulfur-containing amino acid not used in protein synthesis, but 
derived from the intracellular metabolism of methionine (fig. 4). Any excess of intracellular 
Hcy is transported into plasma, where approximately 70 % of Hcy is bound to albumin and 
30 % is oxidized to disulfides (Hcy-Hcy), so-called free oxidized Hcy (74). A small portion 
of Hcy, 1 – 3 %, is in free reduced form (rHcy). The normal range of total Hcy (tHcy) in the 
healthy population is 3 to 15 µmol/L (75).  
 
 
 
 
 
Figure 4. Homocysteine metabolism. 
 
1.5.2 Hyperhomocysteinaemia 
 
For decades it has been noted that high plasma concentration of Hcy is associated with 
CVD. However, although experimental studies have shown that Hcy causes endothelial 
dysfunction, reduced bioavailability of nitric oxide and increased smooth muscle cell 
proliferation, the causality remains unclear (76-79). Elevated plasma concentration of tHcy 
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has been suggested as an independent and graded risk factor for CVD in the general 
population as well as in CKD patients (80-83). 
Circulating tHcy exists mainly bound to plasma albumin and as a consequence plasma 
levels of tHcy are lower in CKD patients with hypoalbuminemia than in those with normal 
plasma albumin. Low serum albumin is associated with protein-energy wasting, which is a 
confounding factor when analyzing tHcy in dialysis patients, as many patients have 
inflammation. Therefore, low concentration of tHcy, rather than high, indicates poor 
outcome in HD patients and Hcy is one of several reversed risk factors in CKD patients 
(84-86). In a clinical study, 459 HD patients were divided into two groups, one with 
protein-energy wasting and one without signs of inflammation. Here tHcy was inversely 
related to all-cause mortality in patients with protein-energy wasting, while a direct 
association was seen in patients without protein-energy wasting inflammation (87). 
 
1.6 INTERVENTIONS  
1.6.1 Vitamins 
 
In the Heart Outcome Prevention Evaluation (HOPE) study, 5,522 patients with diabetes or 
vascular disease were randomized to placebo or a combination of B vitamins. The group 
treated with vitamins showed reduced tHcy levels, but there were no significant benefits in 
outcome over a 5-year follow-up period (88). A new Cochrane review (2015) confirms that 
supplementation with vitamin B6, B12 and folic acid does not prevent cardiovascular events 
in patients with or without pre-existing CVD and no more randomized trials are needed to 
assess this question (89, 90). In accordance with studies of patients with CVD, a study of 
510 dialysis patients treated with high-dose folic acid for 24 months was performed. The 
patients treated with high-dose folic acid had the same rate of cardiovascular events as 
untreated patients (91, 92). Large intervention studies with supplementation of vitamin B12 
and folic acid to dialysis patients show reduced plasma Hcy, but no improvement in the 
number of cardiovascular events or progression rate of atheroma plaques. There are no 
available data supporting the use of folic acid or B vitamins to improve survival in CKD 
patients (90, 93). 
1.6.2 Dialysis 
 
Despite improvements in hemodialysis and peritoneal dialysis technology, the prevalence 
of CVD is high and accounts for more than 50 % of premature death in this population (1). 
In addition to traditional risk factors like hypertension, dyslipidemia and diabetes mellitus, 
non-traditional risk factors like disturbed mineral metabolism, vascular calcification, 
hyperhomocysteinaemia, persistent inflammation and oxidative stress are highly prevalent 
in dialysis patients (94, 95). The low-grade inflammation is usually detected via CRP, but 
other markers like PTX3 and IL6 contribute to understanding the inflammatory process in 
the vasculature (96). In Stockholm, 80 % of prevalent hemodialysis patients in 2005 had 
CRP > 2 mg/L (Fig. 5). 
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Figure 5. The cumulative frequency of elevated CRP in 304 incident end-stage renal disease patients (black 
line) starting dialysis therapy and 231 prevalent hemodialysis (dotted line) patients treated in Stockholm, 
Sweden, 2005. (With permission from Peter Stenvinkel “Inflammation in end-stage renal disease: the hidden 
enemy” (96)). 
 
The prevalence of inflammation differs markedly between different regions of the world 
and the prevalence of increased CRP is lower in HD patients in Asia than in Europe, 
possibly caused by genetic and dietary differences (97). Treatment with nonspecific 
inhibitors of inflammation, such as aspirin and statin medication, is a possible option, but 
convincing evidence is lacking. To reduce the inflammatory burden of dialysis patients, it is 
beneficial to use ultra-pure dialysis fluid and biocompatible dialysis membranes as well as 
minimizing infections of access sites. The inflammatory reaction in HD patients is affected 
by the choice of dialyzer and modality (98). Pilot studies in a limited number of patients 
have reported that CRP levels are lower in patients treated with biocompatible membranes 
than when cuprophan membranes were used (99, 100). Fassett et al observed that HD 
patients with diabetes included in the 4D-study of atorvastatin treated with high-flux had a 
reduced mortality risk compared to those on low-flux membranes   (101).  
Hemodialysis patients treated for 3 hours 6 times a week (short daily HD) showed 
decreased plasma levels of inflammatory markers and a reduction of ventricular 
hypertrophy compared with HD patients on conventional dialysis regimens with treatment 
for 4 hours 3 times a week (102). Evidence that frequent dialysis regimens are beneficial is 
lacking. An observational study by Suri et al. (2013), comparing in-centre daily HD with 
conventional HD (15.7 and 11.9 weekly hours respectively), showed that patients with daily 
HD had a higher mortality rate than patients receiving conventional HD (103). 
 
Concerning inflammation in HD patients, the purity of the dialysate is important. After a 
switch from conventional to online-produced ultrapure dialysate, lower circulating levels of 
CRP and IL6, improved nutritional status and lower cardiovascular morbidity have been 
observed (104, 105). Treatment with peritoneal dialysis (PD) also induced inflammation by 
impurity and/or bio-incompatibility of PD solutions (106).  
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1.6.3 Anti-inflammatory and anti-oxidative interventions 
 
There is an interest in anti-inflammatory nutritional treatment and small studies have 
suggested that omega-3 fatty acids lower the inflammatory response in HD patients and HD 
patients eating fish have better survival (107, 108). Other nutritional factors of interest are 
soy, green tea and pomegranate juice, although evidence of protective effects is missing 
(109-111). Hemodialysis treatment with hydrogen-enriched solution is frequently used in 
Japan and may reduce oxidative stress during HD (112). A small pilot study of 28 patients 
with CKD stage 2 – 3 has shown that low-fructose diet reduces plasma levels of 
inflammatory markers and lowers the blood-pressure (113). In addition, a randomized study 
with supplementation of probiotics or placebo to 39 PD patients for one year, showed 
significant reduction of plasma inflammatory markers (114).  
Convincing studies of beneficial effects of anti-inflammatory interventions as regards 
protecting CKD patients from CVD are lacking. In the 4D-study, a randomized, double-
blind, prospective, multicenter study of 1,255 patients with type 2 diabetes mellitus and on 
maintenance HD treated with atorvastatin or placebo, no effect on CRP was observed. 
Atorvastatin had no significant effect either on cardiovascular death or all-cause mortality, 
or on non-fatal myocardial infarction or stroke in this population (115). Treatment with 
angiotensin converting enzyme inhibitor (ACEI) reduces plasma levels of PTX3 in diabetic 
CKD patients (116, 117). Sevelamer and vitamin D have also been suggested as drugs with 
anti-inflammatory effect in CKD patients but until now there is no established treatment 
recommendations (118). 
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2 THE AIMS OF THE STUDIES 
2.1 OVERALL AIMS 
The overall aim was to evaluate the association of selected biomarkers to the progression of 
CKD and cardiovascular risk in  
1 The general population. 
2 Patients with chronic kidney disease stage 2 – 5.   
3 Dialysis patients. 
 
2.2 SPECIFIC AIMS 
1 To determine plasma reduced Hcy levels in patients with CKD (Paper I). 
2 To determine the association between the inflammatory marker PTX3 and 
progression of chronic kidney disease in two community-based cohorts (Paper II). 
3 To determine the variation and association to mortality of plasma PTX3, CRP, 
albumin and Hcy in hemodialysis patients, over a three-month period (Paper III). 
4 To determine the role of PTX3 as a sensitive early marker of hemodialysis-
induced inflammation (Paper IV). 
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3 METHODS 
 
3.1 STUDY POPULATIONS 
3.1.1 Study one 
 
Seventy-eight patients treated at the department of renal medicine, Karolinska University 
Hospital, Stockholm, were included. Thirty-one patients were on dialysis (19 HD and 12 
PD) and 47 patients non-dialyzed with CKD stage 3 – 5 with an estimated GFR ranging 
from 6 – 57 mL/min*1.73 m2 (MDRD formula) (119). Fifteen healthy persons from the 
general population, matched with the patient groups with respect to sex and age, served as a 
control group. Of the HD patients, 17 had conventional HD treatment three times a week 
and 2 HD patients twice a week, altogether with a mean of 11.4 h/week with low-flux 
membrane (Polyflux 17L, Gambro AB, Lund, Sweden), while one patient had high-flux 
membrane (Polyflux 201H, Gambro AB, Lund, Sweden) and one patient had 
hemodiafiltration (HDF). Median single-pool Kt/V for urea was 1.6 (1.1 – 2.0). 
Eleven PD patients were treated with continuous ambulatory PD (CAPD) and one patient 
with automated PD (APD); all but two CAPD patients used icodextrin (Extraneal, Baxter) 
at night. Median weekly Kt/V for PD patients was 2.2 ± 0.4. 
All patients were on their regular medication and 50 % were prescribed vitamin B and C 
(Oralovite) including thiamine, riboflavin, pyridoxine chloride, nicotine amide and ascorbic 
acid. 
3.1.2 Study two 
3.1.2.1 The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS).  
All men and women at 70 years of age living in Uppsala, Sweden 2001 to 2004 were 
invited to participate in the PIVUS study, described in detail on 
http://www.medsci.uu.se/pivus.htm (120). Of 2,025 invited individuals, 1,016 agreed to 
participate and 768 individuals had data on PTX3 levels and albumin creatinine ratio 
(ACR). A second examination cycle of PIVUS was performed from 2006 to 2009, when the 
participants were 75 years old. Of 964 invited individuals, 827 participated (86 %), and data 
on PTX-3 and estimated GFR were available in 768 individuals. There was no urine sample 
collected at the first examination at 70 years of age, therefore the second examination at 75 
years of age was used for cross-sectional analyses of association between PTX-3 and eGFR 
and ACR respectively. The first examination, when the participants were 70 years old, was 
used as the baseline for longitudinal analyses of PTX3 and decline of eGFR. 
3.1.2.2 The Uppsala Longitudinal Study of Adult Men (ULSAM). 
The ULSAM study started in 1970 when all 50-year-old men, born 1920 – 24 and living in 
Uppsala, Sweden, were invited to participate in a health survey, described in detail on 
http://pubcare.uu.se/ULSAM (121). We used the 4th examination cycle, when the 
participants were 77 years old (1998 – 2001), at baseline. Of 1,398 invited men, 838 (60 %) 
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participated and for 651 individuals data on PTX3 and GFR was available. We used the 5th 
examination cycle of ULSAM (2003 – 2005), when the participants were 82 years old, to 
identify those who had progressed to CKD. At 82 years of age, all 952 men still living were 
invited; a total of 530 (56 %) men agreed to participate and 315 individuals who had data 
on PTX3 and eGFR were included.  
 
Table 2. Baseline characteristics of PIVUS and ULSAM. 
Variable PIVUS  ULSAM 
Number of subjects 768 651 
Female, n   393 (51 %) 0 (0 %) 
Age, (years)   75.3 ± 0.2 77.5 ± 0.8 
CRP, (mg/L) 2.1 (2.8) 2.4 (1.5)  
Pentraxin 3, (ng/ml) 1.8 (3.3) 2.1 (1.3) 
Cardiovascular disease (CVD), n 157 (20 %) 175 (27 %) 
Estimated glomerular filtration rate, (mL/min/1.73 m2)   68 ± 19 74 ± 17 
Urinary albumin/creatinine ratio, (mg/mmol) 1.3 (2) 0.8 (1.8) 
Body mass index, (kg/m2) 26.8 ± 4.3 26.3 ± 3.5 
Systolic blood pressure, (mmHg) 149 ± 19 151 ± 21 
Antihypertensive treatment, n 370 (48 %) 313 (48 %) 
Cholesterol, (mmol/L) 5.5 ± 1.1 5.4 ± 1.0 
High Density Lipoprotein, (mmol/L) 1.5 ± 0.5 1.3 ± 0.3 
Lipid lowering treatment, n 206 (27 %) 118 (18 %) 
Smoking, n 47 (6 %) 45 (7 %) 
Diabetes, n 106 (14 %) 92 (14 %) 
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3.1.3 Study three 
 
The cohort is a subgroup of the individuals from the Mapping of Inflammatory Markers in 
Chronic Kidney Disease (MIMICK), prevalent hemodialysis patients from 6 dialysis units 
in Stockholm and Uppsala (Sweden) (122). At start 254 patients were invited; after 
exclusions for reasons such as unwillingness to participate or contagious infections, 228 
HD patients were included. Out of these, we included the 188 HD patients who had two 
consecutive measurements of CRP, PTX3, albumin and Hcy three months apart. 
 
3.1.4 Study four 
 
Twenty-two prevalent hemodialysis patients, who had been on dialysis for 3 months or 
more, were recruited. Twenty patients were treated at a limited-care HD center and two 
patients were dialyzed at a hospital unit. Patients with immunosuppressive therapy, ongoing 
infection or active inflammation were excluded. The patients were dialyzed for four hours 
three times a week or more, using bicarbonate dialysate and low-flux membranes (PolyFlux 
21L, Gambro, Sweden) with blood flow (Qb) 250 – 330 mL/min. The control group was a 
selection of 61 population-based healthy subjects (42 male and 19 female, mean age 59 ± 
14 years), used for comparative analyses. 
 
3.2 STUDY PROCEDURE  
3.2.1 Study one 
 
In all patients and healthy subjects, blood samples were taken sometime between 7 and 9 
am after an overnight fast. In HD patients, blood was taken before and after a single HD 
session and they were only allowed to have tea or coffee with bread, butter and jam during 
the HD treatment not to affect the methionine metabolism. 
 
3.2.2 Study two 
 
In both PIVUS and ULSAM cohorts, the investigations were performed with similar 
standardized methods, including blood sampling, blood pressure and questionnaires 
regarding medical history, medication, smoking habits, physical activity and socioeconomic 
status (120, 121). 
 
3.2.3 Study three 
 
Data for comorbidity were classified in the same way as in Davies et al., on a 0 to 7 point 
scale including chronic and active conditions. The risk grading 1 – 3 was determined based 
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on number of comorbidities: low risk (no comorbidity), medium risk (score 1 – 2) or high 
risk (score ≥ 3) (123).   
Nutritional status was categorized using the subjective global assessment (SGA), BMI, lean 
body mass index (LBMI) and fat body mass index (FBMI). In 188 HD patients, plasma 
samples for measurements of PTX3, CRP, albumin and Hcy were taken twice, before start 
of a dialysis session on the same weekday with three months in between. The samples were 
centrifuged at 2,500 g for 20 minutes at 4 °C and kept frozen at -70 °C unless immediately 
analyzed. During the follow-up period of 41 months, 88 individuals (47 %) died. 
 
3.2.4 Study four 
3.2.4.1 PTX3 during a HD session in 22 patients 
During a midweek HD session, when the patients had been without dialysis treatment for 
one day, plasma samples were taken at 0, 30, 60, 120, 180 and 240 minutes during the HD 
treatment. The dialysis was standardized, all patients had a four hour dialysis treatment with 
blood flow 250 – 330 mL/min, dialysate flow rate 500 mL/min and as anticoagulant 
tinzaparin sodium (Innohep©, Leo Pharma, Sweden). 
3.2.4.2 PTX3 during repeated HD sessions 
In a subgroup of seven patients, we repeated the same schedule (samples at 0, 30, 60, 120, 
180 and 240 min) during three HD sessions with low-flux filters, to evaluate if the total 
exposure of the inflammatory marker PTX3 would vary if the time from the previous HD 
treatment was 48 or 72 hours, respectively. 
3.2.4.3 Impact of low-flux or high-flux membranes or hemodiafiltration (HDF) on 
inflammatory markers 
In a subgroup of eleven patients, we repeated the same schedule (samples at 0, 30, 60, 120, 
180 and 240 min) during three HD sessions with low-flux or high-flux membranes or HDF, 
to evaluate the effects of filters and dialysis modality on the measured inflammatory 
markers. 
3.2.4.4 Impact of vascular access puncture on PTX3 release 
In a subgroup of ten patients, we performed needle puncturing of the fistula one hour before 
the start of the dialysis treatment to see if the puncturing itself had an impact on PTX3 
plasma levels. Plasma samples were obtained after insertion of the needles (- 60 min) and 
just before the HD start (0 min).  
Result: The vascular puncture did not affect PTX3 levels during the following HD 
treatment.  
3.2.4.5 Correction for ultrafiltration (UF) 
Most HD patients gain weight between the HD sessions because of an inability to produce 
urine. During the HD treatment, aside from clearance of uremic toxins, excess fluid is 
removed from the patient and this induces hemo-concentration and increased 
concentrations in plasma. Therefore, we have corrected the concentrations of PTX3, IL6, 
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TNFα and hsCRP taken during HD for net UF using the formula: 
 
Measured concentration / (1 + Δ BW/0.2 BW) = Concentration corrected for UF 
 
The ΔBW is the change in bodyweight (BW) during HD and the extracellular volume is 20 
% of the post-dialysis BW, assuming linear UF during HD (124). 
 
3.3 BIOCHEMICAL ANALYSIS 
3.3.1 Homocysteine 
3.3.1.1 Study 1 
Blood was collected for analysis of plasma concentrations of reduced, free (non-protein-
bound disulfides) and protein-bound species. Total plasma concentration of Hcy (tHcy) is the 
sum of all three forms of Hcy. The procedure was to take blood samples in cooled EDTA 
tubes and centrifuge at +4 °C at 5,100 g for 5 minutes. Plasma was separated from red blood 
cells and analyzed fresh to determine free and reduced Hcy within 24 hours. Analysis of total 
Hcy in plasma could wait and samples were stored at -70 °C until analysis (Fig. 6). The 
techniques for separation and analysis of the different forms of Hcy are thoroughly described 
in paper 1 (125, 126). 
 
 
 
 
 
Figure 6. Techniques for separation and analysis of the different forms of Hcy.  
4-fluoro-7-sulfobenzofurazan (SBDF), high-pressure liquid chromatography (HPLC),  
trichloroacetic acid (TCA), tri-n-butylphosphine (TBP). 
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3.3.1.2 Study 3 
Total Hcy was analyzed using an immunometric assay on an Immulite© 1000 Analyzer 
(Siemens Healthcare Diagnostics, Los Angeles, CA, USA) according to the instructions of 
the manufacturers. 
 
3.3.2 Pentraxin 3 
3.3.2.1 Study 2 
The plasma PTX3 concentration was analyzed using a commercial available enzyme-linked 
immunosorbent assay (ELISA) kit (DY1826, R&D Systems, Minneapolis, MN, USA). 
3.3.2.2 Study 3 
The plasma PTX3 concentration was measured using a commercially available ELISA kit 
(Perseus Proteomics Inc., Tokyo, Japan). 
3.3.2.3 Study 4 
The blood samples were taken just before the start of the dialysis treatment (0 minutes), 
during the dialysis treatment at 30, 60, 120 and 180 minutes, and at the termination of the 
dialysis at 240 minutes. The first sample was collected from the arterial needle before 
connecting to the dialyzer. The following samples were collected from the afferent sampling 
port without changing the blood flow. 
The PTX-3 concentration was measured using the same type of ELISA kit as in study 3 
(Perseus Proteomics Inc, Tokyo, Japan). 
 
3.3.3 Cystatin C 
3.3.3.1 Study 2 
Cystatin C was measured with a latex-enhanced reagent (N Latex Cystatin C; Siemens, 
Deerfield, IL. USA) using a BN ProSpec analyzer (Siemens) and the data were used to 
estimate GFR in ULSAM with the formula eGFR = 77.24 * cystatin C
-
¹·²⁶². In PIVUS, 
Gentian, Moss, Norway was used and eGFR was calculated using the formula eGFR = 
79.901 *cystatin C
-
¹·⁴³⁹ (127, 128). 
 
3.3.4 CRP and other inflammatory markers 
3.3.4.1 Studies 1 and 3 
hsCRP was measured using an immunometric assay from Immulite© 1000 Analyzer 
(Siemens Healthcare Diagnostics, Los Angeles, CA, USA). 
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3.3.4.2 Study 2 
Measurements of hsCRP were performed with a latex enhanced reagent (Dade Behring, 
Deerfield, IL, USA) using a Behring BN ProSpec analyzer (Dade Behring).    
3.3.4.3 Study 4 
The serum levels of IL6, TNFα and hsCRP were quantified on the Immulite© automatic 
analyzer (Siemens Healthcare Diagnostics, Los Angeles, CA, USA). 
 
3.3.5 Others 
Laboratory analyses of creatinine, urea, albumin, hemoglobin, folate and vitamin B₁₂ were 
determined using routine procedures at the local Department of Clinical Chemistry in papers 
I-IV. There is one exception; in article IV, albumin was determined with a fully automated 
routine method using bromcresol green on a Konelab 20XT centrifugal analyzer (Thermo 
Electron Corporation, Vantaa, Finland). 
 
3.4 STATISTICAL ANALYSIS 
3.4.1 Paper I 
Data are given as mean  standard deviation (SD) or median (range). One-way ANOVA or 
the Kruskal-Wallis one-way analysis of variance was used to evaluate differences between 
groups. The Student’s t-test for paired comparisons was used to evaluate the differences 
between samples taken before and after HD. The association between variables was evaluated 
using Pearson’s correlation coefficient or the Spearman rank-order correlation coefficient. 
Statistical significance was accepted at a p-value < 0.05 (two-tailed).  
  
3.4.2 Paper II 
Normally distributed continuous variables are presented as mean ± SD, skewed continuous 
variables as median (interquartile range) and categorical variables as n (%). To assess cross-
sectional associations between PTX3 and GFR as well as ACR (expressed per 1 SD 
increase), we used multivariable linear regression models. The following multivariable 
models were used: A – Age- and gender-adjusted model (gender is only relevant in the 
PIVUS cohort). B – Inflammatory model (age, gender and CRP). C – Cardiovascular risk 
factor model (age, gender, CRP, smoking, BMI, systolic blood pressure, HDL cholesterol, 
total cholesterol, diabetes mellitus, antihypertensive treatment and lipid lowering treatment).  
The longitudinal association between PTX3 levels at baseline and in patients with incident 
CKD (defined as GFR < 60 mL/min/1.73 m
2
) at a re-examination after 5 years were 
investigated in both cohorts where the same multivariable models A-C were used. In these 
models, all individuals with GFR < 60 mL/min/1.73 m
2
 at baseline were excluded. In both 
cohorts, we also investigated whether baseline PTX3 level predicted change in GFR 
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(ΔGFR) after 5 years, using multivariable regression models adjusted for age at baseline 
and follow-up and baseline GFR. In the PIVUS cohort, where data on PTX3 and GFR were 
available both at baseline and follow-up, we investigated the association between the 
change in PTX3 (ΔPTX3) and change in ΔGFR between baseline and follow-up after 5 
years, using multivariable linear regression models adjusted for age at baseline and follow-
up and baseline GFR (to avoid regression towards the mean). The statistical software 
package STATA 12.1 (Stata Corp, College Station, TX) was used.  
 
3.4.3 Paper III  
The patients were grouped based on which tertile (33rd and 66th percentiles) their baseline 
and 3-month levels of PTX3, CRP, albumin and Hcy fell in. For PTX3, the 33rd and 66th 
percentiles were 7.9 and 13.6 ng/mL for the baseline measurements and 6.9 and 12.1 ng/mL 
for the 3-month measurements. 
High tertile
Middle tertile
Low tertile
High tertile
Middle tertile
Middle tertile
Low tertile
Baseline
Stable
high 
group
Increase
group
Decrease
group
Stable
low
group
Three months
High tertile
High tertile
Middle tertile
Middle tertile
Low tertile
Middle tertile
Low tertile
 
Figure 7. Classification of trimestral variation patterns for PTX3, CRP, albumin and Hcy. 
 
At each time point, individuals were categorized based on each biomarker’s tertiles of 
distribution (low, middle, high). The change in inflammatory markers was categorized based 
on the tertile of distribution of the studied biomarker at each time point. From the nine 
possible combinations, four groups were created by clustering patients with changes in the 
same direction: a) Individuals who showed a decrease in serum levels over the three-month 
period (from high to middle, middle to low, or high to low tertiles) were classified as a 
“decrease” group; b) Individuals showing an increase (from low to middle, middle to high 
and low to high tertiles) were classified as an “increase” group; c) Individuals with both 
values within the highest tertile of distribution were labeled as a “stable high” group; d) 
Individuals with both values within the lower or the middle tertile were labeled as a “stable 
low” group (Fig. 7). The same procedure was applied for each inflammatory mediator and for 
each cohort separately.  
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Normality for all variables was assessed by plotting the frequency distribution and taking into 
account the values of skewness and kurtosis. To test differences between the four groups, 
one-way ANOVA, Kruskal-Wallis and Chi square tests were applied for normally, non-
normally distributed and categorical data respectively. Survival was assessed through the 
Kaplan-Meier analysis and the Cox proportional hazards model, including the above 
mentioned four fluctuation categories for each inflammatory mediator. Since age, sex, 
comorbidities and nutritional status are known to interact with inflammation and influence 
mortality, they were included as confounders in multivariate Cox models. To take into 
account the potential confounding effect of baseline inflammatory levels, the logarithmic 
transformed value was included in both crude and multivariate analyses. All variables 
satisfied the proportional hazards assumption, which was tested by correlating the Schoenfeld 
residuals of each covariate with the survival rank for a specific patient.  
To assess the correspondence between changes of the different inflammatory markers, 
differences over the 3-month period were calculated (ΔCRP, ΔPTX3, Δalbumin, and 
Δhomocysteine) and correlated with each other using Pearson correlation tests. To study the 
within-subject range of variation for CRP, PTX3, homocysteine and albumin in hemodialysis 
patients, we calculated the intra-class correlation (ICC) from estimates of between-subject 
and within-subject variance, derived from mixed model (129). All the statistical analyses 
were performed in SAS version 9.3 (SAS institute, USA). For all hazard ratios, a 95 % 
confidence interval (95 % CI) not including 1, and for all other tests, a p-value < 0.05, were 
considered to be statistically significant.  
 
3.4.4 Paper IV 
All values are expressed as mean ± SD or median [25 – 75 percentiles], unless otherwise 
indicated. A p-value < 0.05 was considered to be statistically significant. Differences between 
time periods were analyzed by analysis of variance (ANOVA) using one-way ANOVA. Area 
under the curve (AUC) calculation of PTX3 levels was performed for each session and 
modality. The AUC was calculated using the trapezoidal method, and incremental AUC 
(IAUC) was calculated by subtraction of the basal PTX3 values. The baseline PTX3 was set 
to 1 in the AUC calculation. We used non-parametric analysis, Wilcoxon Signed Rank test, 
for comparison between two time periods. Because the p-values are not adjusted for multiple 
testing, they have to be considered descriptive. The statistical analysis was performed using 
statistical software SAS version 9.2 (SAS Campus Drive, Cary, NC, USA 27513). 
 
3.5 ETHICAL APPROVALS 
The studies in papers I, III and IV were approved by the Regional Ethical Review Board in 
Stockholm and the study in paper II was approved by the Regional Ethical Review Board in 
Uppsala. 
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4 RESULTS AND DISCUSSION  
 
4.1 PLASMA REDUCED HOMOCYSTEINE IN PATIENTS WITH CKD (STUDY I) 
 
Homocysteine (Hcy) is a sulfur-containing amino acid, derived from the methionine 
metabolism that is dependent on vitamin B and folic acid. Perturbation of the methionine 
metabolism results in accumulation of Hcy, particularly intracellularly (93, 130). Increased 
plasma concentration of tHcy is associated with CVD and progression of CKD in the general 
population (131, 132). Confusingly, there are discrepancies between earlier studies of Hcy 
levels and outcome in HD patients; one study shows that high levels of Hcy correlate with 
increased risk of vascular disease (132) and another study by Suliman et al. (2000) shows that 
low Hcy level is a risk factor for cardiovascular events (133). Interpretation of these 
contradictory findings is difficult, but wasting and hypoalbuminemia are suggested as 
confounders strongly associated with mortality and low tHcy levels. It is believed that the 
reduced form of Hcy, rHcy, is more atherogenic than either oxidized or protein-bound Hcy 
(134) and rHcy levels may therefore provide more information regarding Hcy toxicity than 
tHcy levels. The aim of this study was to examine the relation between the different forms of 
Hcy in dialysis patients (HD and PD) and in patients with CKD stage 3 – 5. In addition, the 
effect of hemodialysis on the different forms of Hcy was investigated.  
In the present study and in agreement with previous studies, the highest levels of tHcy were 
found in PD patients where mean tHcy levels were 2.8 times higher, in HD patients 2.1 times 
higher and in CKD patients 1.9 times higher, compared with in controls. The same pattern 
was seen in fHcy and rHcy. The ratio rHcy/tHcy was significantly higher in dialysis patients 
than in healthy subjects or in CKD patients (Fig. 8). 
 
Figure 8. Ratios of reduced to total Hcy (rHcy/tHcy) in HD patients (n = 19), PD patients (n = 
12) and CKD patients (n = 47). Age- and sex-matched healthy individuals is the control group 
(n = 15). * p < 0.05. 
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There were significant correlations between eGFR and tHcy, fHcy and rHcy and the same 
correlation was observed in the control group. There were no significant differences in 
plasma levels of tHcy, fHcy or rHcy in patients without or with supplementation of vitamin 
B₁, B₂ and B₆. 
All three forms of Hcy were measured before and after a HD treatment in 19 patients. There 
was a 38 % decrease of tHcy level during one HD treatment. A greater decrease of fHcy was 
observed, as free disulfides (fHcy, Hcy-Hcy) are easily removed from plasma and the ratio 
fHcy/tHcy was 39 % before HD and 32 % after HD. Again, the harmful form of Hcy, rHcy 
showed a smaller decrease compared with tHcy and fHcy and the mean ratio rHcy/tHcy 
tended to increase (1.25 % before HD and 1.4 % after HD). The ratio rHcy/fHcy increases 
during HD and mirrors the redox change during HD with a relative increase of rHcy (Fig 9). 
*
   
Figure 9. Plasma reduced to free Hcy (rHcy/fHcy) before and after one hemodialysis treatment (n 
= 19). Control group: Age- and sex-matched healthy subjects (n = 15). * p < 0.05. 
 
This study shows that plasma rHcy concentrations are markedly elevated in CKD patients 
and strongly correlated with tHcy. Our finding of a smaller decrease of rHcy levels during a 
HD treatment, as compared with fHcy and tHcy levels, is of special interest. The greater 
variation in rHcy/tHcy in dialysis patients compared with in CKD patients and controls 
implies that changes in plasma rHcy concentrations do not only mirror changes in plasma 
tHcy levels in this population and that the harmful effect of rHcy may appear even when 
plasma level tHcy is low. 
Two earlier studies of rHcy by Hultberg et al. and Himmelfarb et al. are at odds with our 
observations in the present study. Both groups found low concentrations of rHcy and 
decreasing ratios rHcy/tHcy during HD (135, 136). The study populations differ concerning 
smoking habits, supplementation of vitamin B and folic acid and biochemical methods of the 
different forms of Hcy. Our results are consistent with a study by Ueland et al., which showed 
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elevated plasma rHcy concentrations and also increased rHcy/tHcy ratios in HD and PD 
patients compared with controls (137).  
Treatment with folic acid and vitamin B reduces the plasma concentration of tHcy, although 
several large vitamin intervention trials have shown that lowering the plasma concentration of 
tHcy does not reduce cardiovascular events in CVD patients with normal kidney function nor 
in CKD patients (88, 92, 138). In a large randomized controlled study by Ji et al. (2013), 
vitamin B supplementation for Hcy reduction significantly reduced stroke events (139). 
However, the new Cochrane review of 12 randomized controlled trials of Hcy-lowering 
intervention involving 47,000 individuals found no evidence of reduced risk of 
cardiovascular events through vitamin B treatment (89). 
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4.2 ASSOCIATION BETWEEN THE INFLAMMATORY MARKER PTX3, 
GLOMERULAR FILTRATION RATE AND CKD INCIDENCE IN TWO 
COMMUNITY-BASED COHORTS (STUDY II) 
 
 
Routine laboratory tests, for example of creatinine and urea levels, are insensitive for 
identifying reduced kidney function, especially in early stages of CKD. During the last 
decade, many new biomarkers have been tested for early identification of kidney damage or 
kidney disease (140, 141). In a study from Copenhagen, elevated PTX3 level at admission is 
a strong predictor of short-term mortality in a community-based hospital setting (142). 
In this study, plasma levels of the inflammatory marker PTX3 were analyzed in two large 
community-based cohorts of elderly in Uppsala, ULSAM and PIVUS. In these cohorts, 
higher PTX3 was associated with lower GFR in cross-sectional analyses.  
 
Table 3. The cross-sectional association between PTX3 and GFR and ACR: Linear 
multivariate regression of the ULSAM and PIVUS cohorts. 
ULSAM 
Model A Model B Model C 
GFR -0.12 (-0.19 – (-0.04))** -0.10 (-0.18 – (-0.02))* -0.09 (-0.16 – (-0.01)) * 
ACR 0.08 (0.0 – 0.15) 0.05 (-0.02 – 0.12) 0.05 (-0.03 – 0.12)  
PIVUS 
GFR -0.15 (-0.22 – (-0.08))*** -0.14 (-0.21 – (-0.07))*** -0.16 (-0.23 – (-0.10)) *** 
ACR 0.05 (-0.02 – 0.12) 0.04 (-0.03 – 0.11) 0.05 (-0.03 – 0.11) 
Data are Β-coefficients per standard deviation increment (95 % confidence intervals) ***p < 0.001, **p < 0.01, 
*p < 0.05. GFR = estimated glomerular filtration rate (Cystatin C); ACR = urinary albumin creatinine ratio 
Models: A- age and gender (PIVUS only), B- age, gender (PIVUS only) and CRP, C- age, gender (PIVUS 
only), CRP, smoking, BMI, systolic blood pressure, diabetes mellitus, HDL, cholesterol, antihypertensive and 
lipid treatment. 
 
Our findings are in concordance with prior studies showing an association between PTX3 
and advanced CKD (143, 144), but data on PTX3 and CKD in the general population is 
lacking. There is a large North American multi-ethnic study of a cohort of 2,824 men and 
women, with mean age 61 (45 – 84) years and without CVD or CKD (defined as Cystatin C 
estimated GFR > 60 mL/min/1.73 m²), in which high PTX3 was associated with lower 
GFR, even after adjustments for demographics, comorbidities and IL6. When analyzing 
racial subgroups (26 % blacks, 19 % Hispanic, 34 % Chinese and 20 % whites), this 
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association was strong among blacks but non-significant among Hispanics, Chinese or 
whites (145). 
Moreover, in longitudinal analyses, our study showed that higher PTX3 significantly 
predicted CKD incidence in both cohorts. We are not aware of any previous study reporting 
on the longitudinal association between PTX3 levels and CKD incidence in a community-
based setting. In the ULSAM cohort, baseline PTX3 also predicted GFR decline and in the 
PIVUS cohort there was a close association between longitudinal changes in PTX3 and 
changes in GFR over 5 years. In contrast, no association was seen either between PTX3 
levels and albuminuria in cross-sectional or in longitudinal analyses of ULSAM and PIVUS 
cohorts.  
 
 
Table 4. Longitudinal analyses: Multivariate logistic regression of the association between 
PTX3 and the development of CKD (defined as GFR < 60 mL/min/1.73 m²) in the ULSAM 
(77 and 82 years, number of events/numbers at risk 206/315) and PIVUS (70 and 75 years, 
number of events/numbers at risk 229/746) cohorts, respectively. 
 
 Odds ratios with 95 % confidence intervals 
 ULSAM PIVUS 
Model A 1.33 (1.05 – 1.70) * 1.13 (0.96 – 1.34) 
Model B 1.33 (1.04 – 1.69) * 1.13 (0.96 – 1.34) 
Model C 1.37 (1.07 – 1.77) * 1.21 (1.01 – 1.45) * 
Significance level * p < 0.05. Model A: Age (at the baseline and the follow-up examination) and gender 
(PIVUS) Model B: Age at baseline and follow-up, sex (PIVUS), and CRP Model C: Age at baseline and 
follow-up, sex (PIVUS), and CRP, BMI, smoking, systolic blood pressure, HDL, Cholesterol, diabetes, and 
antihypertensive and lipid. 
 
 
The mechanism by which PTX3 is associated with CKD remains unclear, but higher PTX3 
is related to vascular inflammation, indicating that inflammation and accordingly 
atherosclerosis is present already in mild and often undetected CKD. The properties of 
PTX3 may be helpful in early identification of patients at risk for CVD. In a recent study, 
circulating PTX3 seems to have the potential to be a marker of renal protective effects of 
atorvastatin medication. In patients with raised PTX3 at baseline the decline of GFR during 
the follow-up period of 2.5 years was significantly smaller in patients treated with 
atorvastatin than in those given a placebo (101).  
Finally, PTX3 is a promising kidney damage biomarker already prior to the development of 
overt CKD. 
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4.3 THREE-MONTH VARIATION OF PLASMA PTX3 COMPARED WITH CRP, 
ALBUMIN AND HOMOCYSTEINE (STUDY III) 
 
In this study we compared the four different biomarkers Hcy, albumin, CRP and PTX3 
based on two measurements of trimestral variation and mortality risk in 188 prevalent HD 
patients. This is the first study to show repeated measurements of PTX3 in a dialysis 
cohort.  
4.3.1 Variability 
We found that PTX3 is highly variable within individuals, even more so than CRP, and that 
the trimestral variation of PTX3 between the two measurements was associated to 
mortality. From the variation of PTX3, CRP, albumin and Hcy, the intra-class correlation 
(ICC) was calculated and the within-subject variation was most pronounced for PTX3, 
having the lowest ICC (44 %); accordingly, repeated measurements of PTX3 over time in 
the same individuals will yield more disparate results. The ICC for Hcy is 81 %, indicating 
that most of the observed variability is explained by between-subject variation and 
consequently the within-subject variation is low, implying greater stability within 
individual patients upon repeated measurements over time (Fig. 10).  
 
   
 
Figure 10. Variance components for PTX-3, albumin, CRP and Hcy in HD patients. The ICC 
was calculated from estimates of between-subject and within-subject derived from mixed models.
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4.3.2 Mortality risk 
 
4.3.2.1 PTX3 and CRP and mortality risk 
The mortality risk for trimestral groups was assessed for PTX3, CRP, albumin and Hcy as 
crude and adjusted HRs. During the follow-up period of 41 months, 88 patients died (47 %). 
Patients in the “albumin stable high group” had the best survival rate. PTX3 and CRP were 
positively associated with a higher mortality risk, while albumin and Hcy were negatively 
associated with higher mortality risk. After adjustments for clinical factors the “PTX3 stable 
high group”, the “CRP increase group” and “CRP stable high group” stayed significantly 
associated with high mortality risk compared with stable low groups of these markers (Fig 
11). The variability of CRP (ICC = 0.59) in our study is in agreement with a recent study of 
healthy subjects, which showed an ICC level of 0.62 for CRP. The ICC for PTX3 was 0.44 
and thus had a much higher intra-individual variation, which may reflect more rapid changes 
for PTX, produced locally in the vasculature, than for CRP, synthesized in the liver.  
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Figure 11. Kaplan–Meier survival curves for PTX-3, CRP, albumin and Hcy variation groups. 
 
4.3.2.2 Albumin and mortality risk 
Patients in the “albumin stable low group” and in the “albumin decrease group” had higher 
mortality risk compared with those in the “albumin stable high group”. After adjustments for 
sex, age and comorbidity, only the “albumin decrease group” showed significantly higher 
mortality risk, demonstrating that a decreased albumin level is a clinical warning sign (Fig 
11). 
Low serum albumin is associated with poor outcome in dialysis patients (55, 146, 147). 
Albumin is a negative acute-phase reactant with a strong inverse association to inflammation 
in CKD patients and should be considered an inflammatory marker rather than a marker for 
nutritional status in this patient group (148). 
4.3.2.3 Homocysteine and mortality risk 
High homocysteine plasma levels are associated with worse cardiovascular outcome in the 
general population. However, in CKD patients, there is an inverse association between Hcy 
levels and CVD and mortality (87, 133). This is in accordance with our findings, as patients 
in the “stable low group” of Hcy had significantly increased mortality risk after adjustments 
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for age, sex and comorbidity compared with patients in the “stable high group” of Hcy. This 
inverse relation between low Hcy levels and worse outcome may be explained by 
inflammation and malnutrition in HD patients.  
 
4.3.3 Summary 
PTX3 measurements are less stable and show higher variation within patients (lower ICC 
value, ICC = 0.44) than albumin, CRP and Hcy (ICC = 0.58, 0.59 and 0.81 respectively). 
Persistently elevated PTX3 levels are significantly associated with high mortality and 
accordingly repeated measurements of PTX3 help in predicting mortality risk in HD patients. 
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4.4 PTX3, A SENSITIVE EARLY MARKER OF HEMODIALYSIS-INDUCED 
INFLAMMATION (STUDY IV) 
 
PTX3 stands out as a rapid and sensitive marker of HD-induced inflammation and the 
pattern (149) of the individual PTX3 increase during HD is reproducible.  
 
4.4.1 PTX3 during a HD session in 22 patients 
The median plasma PTX3 of the 22 HD patients increased from 5.8 (3.9 – 8.1) to 8.4 (6.4 – 
10.5) ng/ml, p < 0.001, during a standard HD treatment of 4 hours and the increase was 
significant already after 60 minutes (Fig. 12). The plasma concentration of TNFα showed a 
moderate decrease during the first 30 minutes of the HD treatment, but there were no 
statistically significant changes in IL6 or CRP levels. All values are corrected for UF using 
the Bergström formula: Measured concentration / (1 + Δ BW/0.2 BW) = Concentration 
corrected for UF ((124) and 3.2.4.5).  
 
Figure 12. Box plot of PTX3 (ng/mL); CRP (mg/L), during a 4 hour HD treatment. The values are 
corrected for UF (124). P-values are expressed as significant differences from the baseline value. **p < 
0.01, ***p < 0.001. 
 
 
4.4.2 PTX-3 during repeated HD sessions 
In seven of the 22 patients, we repeated the study procedure in three HD treatments 
(Monday, Wednesday and Friday). The increase pattern of PTX3 was similar in all three 
HD treatments either there were two or three days in between the treatments. There was no 
significance when calculating AUC and IAUC to compare the three HD sessions. 
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4.4.3 Impact of low-flux membranes, high-flux membranes and 
hemodiafiltration (HDF) on inflammatory markers 
 
There was no significant effect on the pattern of PTX3 levels by changing from low-flux to 
high-flux membranes or to HDF with high-flux membrane (Fig 13). 
 
 
Figure 13. Box plot of PTX3 in 11 HD patients with different membrane and modalities; Low-flux (dark grey 
filled boxes), high flux (unfilled boxes) and HDF (light grey filled boxes), during a four-hour HD treatment. The 
values are corrected for UF (124). 
 
The acute-phase protein PTX3 (42 kDa) is a rapid and sensitive inflammatory marker in 
response to dialysis-induced activation of the acute-phase immune system. The protein 
PTX3 is produced locally in the vasculature and can quickly be released from neutrophil 
granulae in response to pro-inflammatory cytokines (IL1, IL10 and TNFα). The acute-
phase reactant CRP (21.5 kDa), a protein of the same family of highly conserved proteins 
as PTX3, both part of the innate immunity, is synthesized in the liver in response to the 
cytokine IL6. In this study, we show that a measurable systemic increase of plasma PTX3 
can be detected in 60 minutes after stimuli (start of HD treatment); however, an increase of 
the systemic plasma level of CRP is not detectable during a standard HD treatment of 4 
hours. The qualities of the protein PTX3 result in new possibilities to measure the 
inflammatory response in different constitutions of the HD treatment, tubing, filters, reverse 
transfer of dialysate contaminants (backflow), purity of water, different dialysis modalities, 
dialysis dose (Kt/V, frequency and weekly hours), needles, blood flow rate, ultrafiltration 
rate, anticoagulant treatment and many more factors.  
To our knowledge, we were the first to study PTX3 levels during HD with different 
membranes and modalities, low-flux membranes, high-flux membranes and HDF with 
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high-flux membranes. We found no significant differences in the increase in PTX3 using 
different HD membranes or treatment modality in this study of 11 patients. The marked 
increase in PTX3 levels during HD sessions and modalities was seen in all patients, and the 
results are reproducible and consistent in all individuals which brings validity to the 
measurements of PTX3 during HD. Similar HD-induced effects on PTX-3 levels have been 
reported by Yamamoto et al (149). Our study cannot eliminate differences in HD modalities 
based on inflammatory activity without further studies with larger study groups. In a 
randomized controlled trial by den Hoedt et al (2014), the patients were treated with HD 
with low-flux filter or HDF for three years. The levels of CRP and IL6 decreased in patients 
with HDF and longtime HDF seems to reduce inflammatory activity compared to HD 
(150). 
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5 SUMMARY AND CONCLUSIONS 
 
5.1 HOMOCYSTEINE 
Homocysteine (Hcy) is a marker of disturbed metabolism in uremia and is suggested as a 
potential cardiovascular risk factor. The underlying effect of Hcy on the vasculature is 
thought to be exerted through the reactivity of the free sulfhydryl group in the reduced form 
of Hcy (rHcy). In our studies we found that 
I rHcy is higher in patients with impaired renal function than in healthy controls. In 
dialysis patients, the ratio of reduced and total Hcy (rHcy/tHcy) is higher than in 
CKD patients and the ratio further increases during a HD treatment (Study I). 
 II the intra-individual variation of Hcy in HD patients is low (Study III). 
III persistently low Hcy levels are associated with a high mortality risk in HD patients. 
The strong link between Hcy and hypoalbuminemia has previously been suggested to 
explain this association (151) (Study III). 
 
5.2 PENTRAXIN 3 
The protein PTX3 is involved in the regulation of the innate immune system and is 
synthesized in the vasculature. It is quickly released from neutrophils after stimuli and 
subsequently detectable in plasma where PTX3 mirrors local inflammation. In our studies we 
have shown that  
I PTX3 can predict the risk to develop CKD (defined as < 60 mL/min/1.73 m²) in the 
elderly (study II). 
II PTX3 has higher variation within patients than CRP, albumin and Hcy according to 
the ICC analysis (study III). 
III persistently high PTX3 levels are associated with a high mortality risk in HD patients 
(study III). 
IV plasma PTX3 concentration shows a significant increase 60 minutes after the start of 
a HD treatment (study IV). 
V the magnitude of the increase of PTX3 during HD did not significantly differ when 
the patients dialyzed with low-flux or high-flux membranes or with HDF (study IV). 
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5.3 STRENGTHS AND LIMITATIONS 
Studies I–III are observational studies with the limitations associated with such studies and 
conclusions regarding causality cannot be drawn. Study IV is an interventional study where 
we measured inflammatory markers in response to different dialysis treatments such as HD 
with low-flux membrane, HD with high-flux membrane and HDF.  
In study I we did map the plasma levels of different forms of Hcy in CKD and dialysis 
patients as the view at that time was that Hcy had a pathogenetic role in vascular disease and 
Hcy-lowering treatment was expected to give survival benefits. Later, large interventional 
studies ruled out advantages of such treatment in the general population as well as in CKD 
and dialysis patients.  
In study II we have longitudinal data from two large cohorts of elderly in Uppsala with 
consistent results from both cohorts. A limitation is that there are only men in the ULSAM 
cohort. 
In study III blood tests were taken in the morning or in the afternoon when patients came for 
their ordinary HD treatment and they were non-fasting. The variation was assessed based 
only on two measurements with three months in between. 
Study IV contains four parts where 22 HD patients or subgroups of these patients were 
included. The results may not be representative for all HD patients as this cohort of HD 
patients was selected from a self-dialysis unit. Of note is the fact that the inflammatory 
burden of these patients is lower than for the general HD population. One of the strengths of 
this study is that we have measurements of PTX3, IL6, TNFα and CRP in parallel with 
achieved ultrafiltration (UF) volume at every 30 – 60 minutes during the HD treatments. All 
values are corrected for UF to avoid overestimation of circulating inflammatory markers due 
to changes in hemo-concentration. 
 
5.4 FUTURE PERSPECTIVES 
The protein PTX3 is a promising marker of inflammation in CKD patients. The role of PTX3 
in the innate system is not fully understood, but recent studies indicate that PTX3 may protect 
against certain infections. Our results suggest an association between high PTX3 levels and 
the development of CKD. The clinical use of PTX3 assessment is not settled, but the protein 
may be a useful marker to monitor infections, complement activation and inflammatory 
diseases as well as vascular diseases and CKD. PTX3 appears to be one of the most sensitive 
markers to study hemodialysis-induced inflammation. In studies of new materials and 
hemodialysis devices, PTX3 has the potential to become a standard method for evaluating 
biocompatibility. 
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Plasma total Hcy, on the other hand, is not as yet a clinically useful biomarker. Several Hcy-
lowering interventions with different combinations of B-vitamins and folic acid have failed to 
show any meaningful clinical benefit. Vascular effects of free reduced Hcy may still be worth 
exploring in prospective clinical studies, but the method is laborious and difficult to apply in 
large cohorts.  
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6 SVENSK SAMMANFATTNING 
 
Personer med kronisk njursvikt har ökad risk för tidig död och majoriteten av dödsfallen är 
till följd av hjärt-kärlsjukdom. Förutom välkända riskfaktorer såsom rökning och förhöjda 
blodfetter är inflammation en riskfaktor för att utveckla hjärt-kärlsjukdom såväl hos 
befolkningen i stort som hos njursjuka. Många studier har gjorts för att närmare förstå 
bakgrunden till den komplexa folksjukdomen hjärt-kärlsjukdom och det har visat sig vara 
många faktorer som samverkar. Ett flertal proteiner är involverade i vårt immunförsvar och 
deras koncentration i blodet förändras vid en inflammatorisk process hos individen.  
Syftet med min avhandling är att undersöka kärl- och inflammationsmarkörer hos njursjuka 
och relatera dessa till risk för död. 
Pentraxin 3 (PTX3) är ett protein som härrör från samma familj som C-reaktivt protein (CRP) 
men har annorlunda egenskaper, bland annat bildas och utsöndras PTX3 direkt från 
kärlbädden och koncentrationen i blodet stiger därför snabbt efter inflammatorisk påverkan. 
Homocystein (Hcy) är en aminosyra som bildas när aminosyran metionin omsätts. Förhöjd 
serumkoncentration av Hcy associerar med ökad risk för död i hjärt-kärlsjukdom hos 
befolkningen i allmänhet. Vid sjunkande njurfunktion ses förhöjda nivåer av Hcy.  
I studie I undersöker vi nivåerna av olika former av Hcy hos individer med kronisk njursvikt, 
med eller utan dialysbehandling. Vi visar att den reducerade formen av Hcy, som antas vara 
skadlig för kärlens insida, är förhöjd vid kronisk njursvikt och stiger ytterligare under en 
enskild bloddialysbehandling.  
I studie II analyserar vi nivåerna av PTX3 hos äldre individer i två befolkningsgrupper 
(kohorter) i Uppsala; The Uppsala Longitudinal Study of Adult Men (ULSAM) och The 
Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS). I den senare var 
hälften kvinnor. Resultaten visar att högre serumnivåer av PTX3 korrelerar med försämrad 
njurfunktion, dvs. sjunkande glomerulär filtration (GFR). Dessutom finner vi, genom 
uppföljning med nya prover efter fem år, att plasmanivån av PTX3 hos individer med normal 
njurfunktion vid första provtagningstillfället kan förutsäga utveckling av njursvikt. 
I studie III undersöker vi fyra inflammationsmarkörer (PTX3, CRP, albumin och Hcy) hos 
patienter som behandlas med regelbunden bloddialys. Prover togs före dialys vid två tillfällen 
med tre månaders mellanrum. Vi analyserar variationen över tid och demonstrerar att PTX3 
har störst individuell variation av de undersökta markörerna. Vi finner även att risken för död 
ökar hos individer med upprepade höga plasmanivåer av PTX3. Därutöver visar vi att 
stigande CRP, sjunkande albumin och upprepade låga värden av Hcy associerar med ökad 
dödlighet. 
Slutligen undersöker vi i studie IV hur koncentrationen av proteinet PTX3 förändras under 
en bloddialysbehandling. Vi tog prover efter 0, 30, 60, 120, 180 minuter och vid dialysens 
slut efter 240 minuter. PTX3 är förhöjt redan vid dialysstart, men därutöver stiger PTX3-
koncentrationen snabbt under själva dialysbehandlingen och ökningen är signifikant redan 
efter 60 minuter. Vi testar olika dialysfilter (låg- och högpermeabelt filter samt 
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hemodiafiltration (HDF) med högpermeabelt filter), men finner ingen signifikant skillnad i 
ökningen av PTX3.  
Sammanfattningsvis så visar vi att PTX3 är en lovande markör för att påvisa inflammation 
och risk för död hos patienter med kronisk njursvikt.  
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